Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5211765 | 0.83 | ALDH1A1 (0.42) | NPC1RAB9AALDH1A1KMT2AKDM4E | |
| SCHEMBL5207866 | 0.83 | GABRA1 (0.35) | ALDH1A1KMT2AKDM4E | |
| SCHEMBL5214089 | 0.80 | KMT2A (0.49) | ALDH1A1LMNAKMT2AMEN1TP53 | |
| SCHEMBL14609752 | 0.80 | TSPO (0.37) | ALDH1A1KMT2AMEN1KDM4EATM | |
| SCHEMBL5211701 | 0.78 | MKNK1 (0.42) | ALDH1A1KMT2AMEN1PLK1 | |
| SCHEMBL5213712 | 0.78 | POLB (0.46) | L3MBTL1TDP1ALDH1A1LMNATP53 | |
| SCHEMBL5211271 | 0.78 | TP53 (0.46) | ALDH1A1KMT2AMEN1TP53THRB | |
| SCHEMBL5213384 | 0.77 | RXRA (0.47) | ALDH1A1KMT2APLK1KDM4E | |
| SCHEMBL1361176 | 0.77 | RAB9A (0.40) | NPC1RAB9AALDH1A1LMNAKMT2A | |
| SCHEMBL5212376 | 0.77 | LMNA (0.45) | L3MBTL1RAB9AALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050090534-A1 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1486490-A1 | AZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090534-A1 | Azole compounds | AHR, NR0B2, NR2C2 | NPC1 3792/4885L3MBTL1 3447/4885RAB9A 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.